Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Attention Deficit Hyperactivity Disorder Market Expected To Expand Between 2025 And 2029?
The attention deficit hyperactivity disorder market size has experienced significant growth in recent years. It is anticipated to expand from $16.29 billion in 2024 to $17.38 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.7%. This historic period’s expansion can be attributed to the rising prevalence of ADHD, the increasing incidence of ADHD in children, enhanced awareness of ADHD, a surge in healthcare expenditure, and various government initiatives aimed at mental health awareness.
The market for attention deficit hyperactivity disorder is projected to experience substantial expansion over the coming years. Its valuation is anticipated to climb to $22.42 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth stems from several factors, including a rise in pediatric and adult patient numbers undergoing treatment, enhanced healthcare infrastructure, increased embrace of personalized medicine, greater public acceptance of mental health conditions, and a heightened consumption of additives and preservatives in children’s diets. Key developments expected during this period encompass technological advancements and novel therapeutic approaches, refinements in diagnostic and treatment protocols, the introduction of new pharmaceutical agents, a move towards non-stimulant drug options, and progress within pharmaceutical treatments.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21108&type=smp
Which Drivers Are Supporting Growth Of The Attention Deficit Hyperactivity Disorder Market?
The increasing embrace of personalized medicine is anticipated to fuel the expansion of the attention deficit hyperactivity disorder (ADHD) market in the future. This medical strategy customizes treatments based on an individual’s genetic makeup, environment, and lifestyle to deliver more accurate and impactful healthcare. The rise of personalized medicine stems from breakthroughs in genomic technologies, allowing therapies to be customized according to a person’s genetic profile, resulting in more potent and specific interventions. Within personalized medicine, attention deficit hyperactivity disorder (ADHD) plays a crucial role by enabling bespoke treatment plans that factor in an individual’s distinct genetic, environmental, and behavioral traits, thereby leading to more successful and targeted treatments. As an illustration, a February 2024 report from the Personalized Medicine Coalition (PMC), a US-based non-profit, indicated that personalized medicines made up more than a third of new FDA drug approvals in 2023, marking the fourth consecutive year for this trend. Specifically, the FDA sanctioned 16 novel personalized treatments for rare diseases (an increase from 6 in 2022), alongside 7 cancer medications, and 3 for various other ailments. Consequently, the increasing use of personalized medicine is propelling the expansion of the attention deficit hyperactivity disorder market.
What Are The Primary Types Of Segments Analyzed In The Attention Deficit Hyperactivity Disorder Market?
The attention deficit hyperactivity disordermarket covered in this report is segmented –
1) By Type: Stimulants; Non-Stimulants
2) By Age Group: Children; Adults
3) By Gender: Male; Female
4) By Dosage Form: Tablets; Capsules; Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications; Amphetamine-based Medications; Mixed Amphetamine Salts; Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera); Guanfacine (Intuniv); Clonidine (Kapvay); Bupropion (Wellbutrin)
What Are The Major Trends Driving The Growth Of The Attention Deficit Hyperactivity Disorder Market?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) market are concentrating on creating innovative medications, such as extended-release tablets, to enhance treatment effectiveness, boost patient adherence, and offer sustained symptom control. Extended-release tablets are formulated to gradually release medication over time, delivering continuous symptom management throughout the day with just one dose, which reduces the necessity for multiple doses and improves convenience and commitment to the treatment plan for individuals with attention deficit hyperactivity disorder (ADHD). For instance, in February 2022, JAMP Pharma Group, a Canada-based pharmaceutical company, introduced Guanfacine XR, a generic version of Takeda Canada Inc.’s INTUNIV XR, a branded medication designed to treat attention deficit hyperactivity disorder (ADHD). It is a long-acting type of guanfacine, functioning by influencing particular receptors in the brain to improve attention, impulse control, and hyperactivity. The drug is accessible in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is supplied in a 100-count bottle, offering adaptability for treatment.
Who Are The Primary Competitors In The Global Attention Deficit Hyperactivity Disorder Market?
Major companies operating in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Attention Deficit Hyperactivity Disorder Market?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Attention Deficit Hyperactivity Disorder Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21108&type=smp
Browse Through More Reports Similar to the Global Attention Deficit Hyperactivity Disorder Market 2025, By The Business Research Company
Attention Deficit Hyperactivity Disorder Adhd Therapeutics Global Market Report 2025
Myeloproliferative Disorders Drugs Global Market Report 2025
Hyperpigmentation Disorder Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model